Upload File

modulating pcsk9 and the ldl receptor: tipping the balance of power

  • Home
  • Documents
  • Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power
15

Upload: billy

Post on 23-Feb-2016

84 views

Category:

Documents


0 download

Report

Tags:

DESCRIPTION

Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power. PRIMO: Observational Study in 7924 Patients. Genetics: PCSK9. PCSK9 Monoclonal Antibody vs Placebo on LDL-C Levels. Dosing and Administration. LAPLACE-TIMI 57: AMG 145 Q2W Dose Response -- Change in LDL-C From Baseline. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power
Page 2: Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power
Page 3: Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power
Page 4: Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power
Page 5: Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power
Page 6: Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power
Page 7: Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power
Page 8: Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power
Page 9: Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power
Page 10: Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power
Page 11: Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power
Page 12: Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power
Page 13: Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power
Page 14: Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power
Page 15: Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power

PCSK9 Inhibitors PP

PCSK9 Inhibition : From Genetics to Patients · PCSK9 mutations and impact on LDL-C\爀屲 PCSK9 mutations represent the major source of variability in PCSK9 expression. Two type\൳

Guia prático para a utilização dos inibidores da PCSK9 em ... · inibidores da PCSK9 são anticorpos monoclonais que se ligam à PCSK9 impedindo-a de se ligar ao recetor do LDL,

Pcsk9 inhibitory

Genetic Variants of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Implications for Low-Density Lipoprotein Cholesterol (LDL-C) © 2014 Amgen Inc

PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange

Familial Hypercholesterolaemia - PCSK9 Forum · Familial Hypercholesterolaemia ... Unilever, Danone , Aegerion ... DNA-based evidence of an LDL-r, apoB-100, or a PCSK9 mutation

Prevalence and relevance of Lp(a) in familial ... · Atherosclerosis Myocardial infarction Angina pectoris Elevated LDL cholesterol Mutations in LDL receptor, apolipoproteinB or PCSK9

Next generation LDL-C management with ALN-PCSsc, an ... · Next generation LDL-C management with ALN-PCSsc, an investigational PCSK9 synthesis ... efficacy and safety of its ... an

Rosuvastatin, pcsk9 concentrations, and ldl cholesterol response the jupiter trial

Fernando-Cruz Foundation Symposium, Hospital Clinico San ... · Rashid S et al. PNAS 2005;102:5374–5379. Role of PCSK9 in regulation of the surface expression of LDL receptors LDL

The Role of PCSK9 in the Regulation of LDL Cholesterol · PCSK9 function, which leads to decreased LDLR recycling to the cell surface.7,9 • This results in an autosomal-dominant

The Chronicles of Berberineassets.a4m.com/assets/webcasts/webcast_pdfs/2013-11-18...2013/11/18  · THE CHRONICLES of BERBERINE C. S. Lewis and R. H. Poling PCSK9, AMPK, and the LDL

Lipid lowering with PCSK9 inhibitors · 2015-01-30 · Phase III trials of PCSK9 inhibitors are providing evidence on the benefit of additional LDL -C lowering in high-risk patients

IR Conference Call on PCSK9 - Biotech Due Diligence...Decreasing CV Risk 8 LDL-C Guidelines Have Evolved to More Rigorous Goals These guidelines have identified people with documented

Fetal gender and gestational age differentially affect ...intrauterine growth restriction (IUGR). Generally, LDL-C catabolism is under control of PCSK9 by binding to the LDL-receptor

Development of Inhibitors of Human PCSK9 as Potential Regulators of LDL-Receptor ... · Development of Inhibitors of Human PCSK9 as Potential Regulators of LDL-Receptor and Cholesterol

Presentación de PowerPoint · 2020. 12. 9. · Tema 3: Incrementadores del R-LDL Estatinas, Ezetimibe y mAbs-PCSK9. Su evolución y estatus en la era Inclisiran Evento patrocinado

Kits PCSK9 ELISA Kit & PCSK9-LDLR in vitro Binding Assay ...€¦ · Human PCSK9 ELISA Kit (#CY-8079) Mouse/Rat PCSK9 ELISA Kit (#CY-8078) -Used for the quantitative measurement of

NEW DRUGS IN CARDIOLOGY PCSK9 INHIBITORS · • Discovery reported in 2003 and 2004 • PCSK9 missense/LOF mutations- ARIC study • African Americans : 28% less LDL-C, 88% lower

An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top ...An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top ... ... 2012, 8

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: … Lp(a) EAS_FINAL.pdf · Lp(a) and Risk of MI ... history of stroke, PAD, HTN, DM, current smoking, baseline LDL-C •

THERAPEUTICS A tale of two drugs - media.nature.com · cholesterol by liver cells, such that lowering PCSK9 expression reduces LDL cholesterol levels in the blood (high LDL levels

The Role of PCSK9 in the Regulation of LDL Cholesterol · 2020. 7. 10. · surface, PCSK9 reduces the concentration of LDLRs on the surface of the hepatocytes, resulting in a lower

Intervention to improve LDL receptor function Emerging Therapies › sites › default › files › 9._cuchel... · 2017-05-26 · ↓Cholesterol ↑ LDLR ↑ PCSK9 ... • Evinacumab

Inclisiran and the ORION programme · Total AMG 145 (evolocumab) Free PCSK9 Free PCSK9 concentration (ng/mL) Free evolocumab concentration (ng/mL x 0.01) LDL-C Stein EA & RaalFJ Annu

The Value of PCSK9 Inhibitors: A Matter of Perspective€¦ · Autosomal dominant inheritance pattern 2. Most mutations occur in the LDL-receptor gene—on chromosome 19 3. Mutations

Paul Ehrlich and PCSK9 inhibition: A Magic Bullet for CVD … · 2020-03-10 · e PCSK9 46L rs11591147 ALLHAT-LLT SEARCH Pharmacologically Lower LDL-C A to Z Genetically Lower LDL-C

New Kids on the Block: The Promise of PCSK9 …...Proprotein convertase subtilisin—kexin type 9 (PCSK9) inhibitors are new agents with robust LDL-C lowering, reported between 50-70%

Update on PCSK9 Inhibitors

La Nuova Terapia...LDLR PCSK9 1. Catalytic domain 2. Prodomain 3. C-terminus PCSK9 is a Regulator of LDL Metabolism • Proprotein convertase subtilisin/kexin type 9 • A serine proprotein

PCSK9 Inhibitors - Impact on the Management of LDL ... · LDL Apheresis Currently, there are more than 400 patients in North America receiving LDL apheresis therapy at more than 40

Presentación de PowerPoint - 147.96.70.122147.96.70.122/Web/TFG/TFG/Poster/PAULA DEL RIO ORTEGA.pdf · La inhibición de la PCSK9 incrementará proporcionalmente los R-LDL y disminuirá

New Horizons in Dyslipidemia Management in Primary … PCSK9 Activity Inhibits Intracellular Degradation of LDL-R Qian YW, et al. J Lipid Res. 2007;48:1488-1498; Horton JD, et al

od 1 do - Jagiellonian University Medical College · 2019. 11. 14. · Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9. BMC Cardiovasc Disord